Loading...
•
Mar 31, 2023
Reviva Q1 2023 Earnings Report
Reviva reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023. The company's cash totaled approximately $11.3 million as of March 31, 2023.
Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023.
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model.
IND submission for brilaroxazine lipogel in psoriasis expected in 2024.
Over 60% of approximately 400 patients have been enrolled in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia.
Forward Guidance
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of March 31, 2023 will be sufficient to fund current operating plans through the third quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...